NEW YORK – PerkinElmer has entered into a $500 million credit facility to pay, in part, its $5.25 billion acquisition of BioLegend, the Waltham, Massachusetts-based company said in a document filed with the US Securities and Exchange Commission on Thursday.
PerkinElmer entered into the unsecured delayed draw term loan credit facility on Aug. 11 with Bank of America as administrative agent. Other lenders include Goldman Sachs, JP Morgan Chase, and Wells Fargo, PerkinElmer said in the SEC document. The credit facility provides for a $500 million committed term loan to fund, in part, PerkinElmer's buy of BioLegend, to refinance certain indebtedness of BioLegend, and to pay fees and expenses associated with the acquisition and its financing.